Vincenzo Somma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vincenzo Somma has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth Davida Paratz
St Vincents Institute of Medical Research
2 shared publications Elizabeth Paratz
St Vincent's Hospital (Melbourne) Limited
2 shared publications- Qing Yi Fang
Department of Cardiology, Royal Melbourne Hospital, Parkville, VIC, Australia
2 shared publications - Adam Trytell
Department of Cardiology, Bendigo Health, Bendigo, Vic, Australia
1 shared publication Aleksandr Voskoboinik
Alfred Health
1 shared publicationAndre La Gerche
St Vincent's Hospital Melbourne, 41 Victoria Parade Fitzroy VIC 3065; Melbourne University, Parkville VIC 3010; Baker Heart & Diabetes Institute, 75 Commercial Rd Prahran VIC 3181
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (6) , ytag425
Cardiac metastasis from a Pancoast tumour presenting with ST-segment elevation and 2:1 atrioventricular block: a case report
Background: Cardiac metastases are significantly more common than primary cardiac tumours. Their clinical presentation varies depending on tumour size, location, and degree of myocardial or pericardial infiltration. Common manifestations include pericardial effusion, valvular dysfunction due to inflow or outflow obstruction, and conduction disturbances. 2:1 atrioventricular (AV) block secondary to cardiac metastases is rare. Case Summary: We report a case of a 69-year-old man with a Pancoast tumour who presented with hyperacute ST-segment elevation and 2:1 AV block. Transthoracic echocardiography (TTE) and positron emission tomography (PET) revealed intracardiac metastases. A permanent dual-chamber pacemaker was implanted for symptomatic 2:1 AV block. The patient died from advanced malignancy shortly after device implantation. Discussion: This case highlights 2:1 AV block as an uncommon manifestation of cardiac metastases. Multimodality imaging, particularly TTE, cardiac magnetic resonance imaging, and cardiac PET, plays a pivotal role in timely diagnosis. Permanent pacemaker implantation in such cases is a challenge in terms of clinical utility and palliative care. Decisions regarding permanent pacing should be shared between the patient and clinicians, incorporating balance between clinical indications, patient’s comorbidities, prognosis, and preferences.
- 1 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (6) , ytag425
Open AccessCardiac metastasis from a Pancoast tumour presenting with ST-segment elevation and 2:1 atrioventricular block: a case report
Background: Cardiac metastases are significantly more common than primary cardiac tumours. Their clinical presentation varies depending on tumour size, location, and degree of myocardial or pericardial infiltration. Common manifestations include pericardial effusion, valvular dysfunction due to inflow or outflow obstruction, and conduction disturbances. 2:1 atrioventricular (AV) block secondary to cardiac metastases is rare. Case Summary: We report a case of a 69-year-old man with a Pancoast tumour who presented with hyperacute ST-segment elevation and 2:1 AV block. Transthoracic echocardiography (TTE) and positron emission tomography (PET) revealed intracardiac metastases. A permanent dual-chamber pacemaker was implanted for symptomatic 2:1 AV block. The patient died from advanced malignancy shortly after device implantation. Discussion: This case highlights 2:1 AV block as an uncommon manifestation of cardiac metastases. Multimodality imaging, particularly TTE, cardiac magnetic resonance imaging, and cardiac PET, plays a pivotal role in timely diagnosis. Permanent pacemaker implantation in such cases is a challenge in terms of clinical utility and palliative care. Decisions regarding permanent pacing should be shared between the patient and clinicians, incorporating balance between clinical indications, patient’s comorbidities, prognosis, and preferences.
- Open Access
- 28 March 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (4) , ytaf156
Purulent pericarditis caused by Streptococcus pyogenes: a case report and review
Background: Purulent pericarditis is rare and associated with significant mortality. We outline a case of Group A streptococcus (GAS, Streptococcus pyogenes) native aortic valve infective endocarditis with associated purulent pericarditis and review the literature. Of the reported cases, most occur in children and have high degrees of mortality. There are no cases that describe GAS purulent pericarditis as a complication of infective endocarditis. Case summary: A 43-year-old female presented with an altered conscious state and refractory hypotension. An urgent transthoracic echocardiogram revealed a vegetation on the aortic valve, moderate-severe aortic regurgitation and a moderate-large circumferential pericardial effusion with evidence of early cardiac tamponade. An urgent pericardiocentesis was performed and drained 500 mL of purulent pericardial fluid. Peripheral blood and pericardial fluid cultures grew GAS. Unfortunately the pericardiocentesis did not improve the patient’s haemodynamics, she developed recurrent malignant arrhythmias culminating in cardiac arrest and was unable to be resuscitated. Discussion: To our knowledge this is the first described case of GAS purulent pericarditis arising from infective endocarditis. This case contributes to the limited evidence regarding GAS-related purulent pericarditis. Management includes multidisciplinary care with timely administration of broad-spectrum antibiotics, prompt drainage, and contemplation of early surgical intervention. Our review of the 20 reported cases of GAS purulent pericarditis reveals that only 6 out of 20 patients were over 18 years old and the mortality ranged from 40% to 85%. A high degree of clinical suspicion is required as more than half of the cases are diagnosed at post-mortem.
- 28 March 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (4) , ytaf156
Open AccessPurulent pericarditis caused by Streptococcus pyogenes: a case report and review
Background: Purulent pericarditis is rare and associated with significant mortality. We outline a case of Group A streptococcus (GAS, Streptococcus pyogenes) native aortic valve infective endocarditis with associated purulent pericarditis and review the literature. Of the reported cases, most occur in children and have high degrees of mortality. There are no cases that describe GAS purulent pericarditis as a complication of infective endocarditis. Case summary: A 43-year-old female presented with an altered conscious state and refractory hypotension. An urgent transthoracic echocardiogram revealed a vegetation on the aortic valve, moderate-severe aortic regurgitation and a moderate-large circumferential pericardial effusion with evidence of early cardiac tamponade. An urgent pericardiocentesis was performed and drained 500 mL of purulent pericardial fluid. Peripheral blood and pericardial fluid cultures grew GAS. Unfortunately the pericardiocentesis did not improve the patient’s haemodynamics, she developed recurrent malignant arrhythmias culminating in cardiac arrest and was unable to be resuscitated. Discussion: To our knowledge this is the first described case of GAS purulent pericarditis arising from infective endocarditis. This case contributes to the limited evidence regarding GAS-related purulent pericarditis. Management includes multidisciplinary care with timely administration of broad-spectrum antibiotics, prompt drainage, and contemplation of early surgical intervention. Our review of the 20 reported cases of GAS purulent pericarditis reveals that only 6 out of 20 patients were over 18 years old and the mortality ranged from 40% to 85%. A high degree of clinical suspicion is required as more than half of the cases are diagnosed at post-mortem.
- Open Access
- 17 February 2025
- Published by Wiley
Cardiac Medications Causing False-Positive Illicit Drug Results: A Case Report.
- 17 February 2025
- Published by Wiley
Open AccessCardiac Medications Causing False-Positive Illicit Drug Results: A Case Report.
- Open Access
- 1 March 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (3) , ytae121
Hypertrophic cardiomyopathy with anteriorly directed mitral regurgitation is a red flag for concomitant pathology: a case report
Background: Hypertrophic cardiomyopathy (HCM) is often linked to systolic anterior motion (SAM) of the mitral valve, typically resulting in a posteriorly directed mitral regurgitation (MR) jet. An anteriorly directed MR jet suggests additional mitral valve pathology that may not be resolved by myectomy alone. Case summary: A 58-year-old construction worker with no significant medical history experienced a syncopal event and was admitted to the emergency department with acute pulmonary oedema. A systolic murmur was investigated with a trans-thoracic echocardiogram that revealed severe MR with an unusual anteriorly directed MR jet and a possible flail segment of the posterior leaflet. This finding was further characterized with a trans-oesophageal echocardiogram that revealed severe asymmetric septal hypertrophy with SAM of the mitral valve, severe mitral regurgitation into a dilated left atrium with pulmonary vein flow reversal not caused by HCM-associated SAM, and a markedly abnormal mitral valve with flail and prolapse. The patient underwent successful cardiac surgery, including mitral valve repair and septal myectomy. The patient’s recovery was uneventful, allowing for a return to work within a month post-surgery. Discussion: The anteriorly directed MR jet served as a red flag, leading to the discovery of an independent mitral valve pathology that required surgical intervention beyond the expected treatment for SAM-associated HCM. This case highlights the complexity of assessing MR in patients with HCM and underscores the importance of characterizing MR jet direction in diagnosing additional mitral valve diseases.
- 1 March 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (3) , ytae121
Open AccessHypertrophic cardiomyopathy with anteriorly directed mitral regurgitation is a red flag for concomitant pathology: a case report
Background: Hypertrophic cardiomyopathy (HCM) is often linked to systolic anterior motion (SAM) of the mitral valve, typically resulting in a posteriorly directed mitral regurgitation (MR) jet. An anteriorly directed MR jet suggests additional mitral valve pathology that may not be resolved by myectomy alone. Case summary: A 58-year-old construction worker with no significant medical history experienced a syncopal event and was admitted to the emergency department with acute pulmonary oedema. A systolic murmur was investigated with a trans-thoracic echocardiogram that revealed severe MR with an unusual anteriorly directed MR jet and a possible flail segment of the posterior leaflet. This finding was further characterized with a trans-oesophageal echocardiogram that revealed severe asymmetric septal hypertrophy with SAM of the mitral valve, severe mitral regurgitation into a dilated left atrium with pulmonary vein flow reversal not caused by HCM-associated SAM, and a markedly abnormal mitral valve with flail and prolapse. The patient underwent successful cardiac surgery, including mitral valve repair and septal myectomy. The patient’s recovery was uneventful, allowing for a return to work within a month post-surgery. Discussion: The anteriorly directed MR jet served as a red flag, leading to the discovery of an independent mitral valve pathology that required surgical intervention beyond the expected treatment for SAM-associated HCM. This case highlights the complexity of assessing MR in patients with HCM and underscores the importance of characterizing MR jet direction in diagnosing additional mitral valve diseases.
- 16 June 2023
- Published by Elsevier in Heart Rhythm
- Vol. 20 (11) , 1525-1531
Epidemiology of pediatric out-of-hospital cardiac arrest compared with adults
- 16 June 2023
- Published by Elsevier in Heart Rhythm
- Vol. 20 (11) , 1525-1531
Epidemiology of pediatric out-of-hospital cardiac arrest compared with adults
- 24 January 2023
- Published by Wiley in Internal Medicine Journal
- Vol. 53 (1) , 21-26
Methamphetamine‐associated cardiomyopathy: an addiction medicine perspective
Methamphetamine-associated cardiomyopathy (MaCM) is an increasingly recognised serious complication from methamphetamine (MA) use. It is characterised as the development of otherwise unexplained heart failure in the context of MA use. MaCM predominantly affects a young and vulnerable population with high morbidity and mortality. It is the second leading cause of mortality in patients with MA use disorder (MUD). Our understanding of MaCM pathogenesis is based on observational cohorts and autopsy studies. Currently, the treatment of MaCM is predicated on abstinence. Medical therapies offer some benefit to a minority of patients; however, without abstinence, medical therapies are often ineffective. Abstinence is difficult for most patients to achieve; all clinicians require an understanding of MaCM and how to educate patients on the risks of ongoing use. Where available, referral to addiction medicine specialists to assist with treatment of MUD is recommended. This review aims to: (i) explain the proposed pathologic mechanisms of MaCM; (ii) summarise recent recommendations of the screening and treatment of MaCM; and (iii) highlight the role of addiction medicine in the management of patient with MaCM.
- 24 January 2023
- Published by Wiley in Internal Medicine Journal
- Vol. 53 (1) , 21-26
Methamphetamine‐associated cardiomyopathy: an addiction medicine perspective
Methamphetamine-associated cardiomyopathy (MaCM) is an increasingly recognised serious complication from methamphetamine (MA) use. It is characterised as the development of otherwise unexplained heart failure in the context of MA use. MaCM predominantly affects a young and vulnerable population with high morbidity and mortality. It is the second leading cause of mortality in patients with MA use disorder (MUD). Our understanding of MaCM pathogenesis is based on observational cohorts and autopsy studies. Currently, the treatment of MaCM is predicated on abstinence. Medical therapies offer some benefit to a minority of patients; however, without abstinence, medical therapies are often ineffective. Abstinence is difficult for most patients to achieve; all clinicians require an understanding of MaCM and how to educate patients on the risks of ongoing use. Where available, referral to addiction medicine specialists to assist with treatment of MUD is recommended. This review aims to: (i) explain the proposed pathologic mechanisms of MaCM; (ii) summarise recent recommendations of the screening and treatment of MaCM; and (iii) highlight the role of addiction medicine in the management of patient with MaCM.
- Top Cited Papers
- 7 November 2022
- Published by Elsevier in Heart Rhythm
- Vol. 20 (2) , 282-290
Pacing-induced cardiomyopathy: A systematic review and meta-analysis of definition, prevalence, risk factors, and management
- 7 November 2022
- Published by Elsevier in Heart Rhythm
- Vol. 20 (2) , 282-290
Top Cited PapersPacing-induced cardiomyopathy: A systematic review and meta-analysis of definition, prevalence, risk factors, and management